Date: 2014-01-10
Type of information: Licensing agreement
Compound: Locked Nucleic Acid (LNA) technology
Company: Santaris Pharma (Denmark) GSK (UK)
Therapeutic area:
Type agreement: licensing
Action mechanism: The LNA Drug Platform and Drug Discovery Engine combines Santaris Pharma\'s proprietary LNA chemistry with its specialized and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against both mRNA and microRNA, thus enabling scientists to develop drug candidates against diseases that are difficult, or impossible, to target with contemporary drug platforms such as antibodies and small molecules. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies through a combination of small size and very high affinity that allows this new class of drugs candidates to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles.
Disease:
Details: * On January 10, 2014, Santaris Pharma has announced that the company has signed an agreement with GSK, whereby, pursuant to an option right, GSK gains access to Santaris\' Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines. Under the terms of the agreement, GSK can obtain rights to utilize Santaris Pharma\'s proprietary Locked Nucleic Acid (LNA) Drug Platform to research, develop and commercialize LNA-medicines targeted against up to three targets.
Financial terms: Financial details on the deal were not disclosed.
Latest news:
